A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2023-07-15
Adverse events
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-09-20 (study day 52); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-01-15 (study day 169); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-01-24 (study day 178); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-04-06 (study day 251); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-04-21 (study day 266); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-04-29 (study day 274); relationship: not assessed
Data queries
No data queries.